Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines

Everolimus (Eve) is an FDA approved drug that inhibits mammalian target of rapamycin (mTOR). It is employed in breast cancer treatment even if its responsiveness is controversial. In an attempt to increase Eve effectiveness, we have developed a novel Eve nanoformulation exploiting H-ferritin nanocag...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmaceutics
Main Authors: Bonizzi, Arianna, Truffi, Marta, Sevieri, Marta, Allevi, Raffaele, Sitia, Leopoldo, Ottria, Roberta, Sorrentino, Luca, Sottani, Cristina, Negri, Sara, Grignani, Elena, Mazzucchelli, Serena, Corsi, Fabio
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6723888/
https://ncbi.nlm.nih.gov/pubmed/31382388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics11080384
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados